Carbamazepine for prevention of chemotherapy-induced nausea and vomiting
a pilot study
Keywords:
Antiemetics, Vomiting, Nausea, Carbamazepine, Prevention and control [subheading]Abstract
CONTEXT AND OBJECTIVE: Nausea and vomiting are major inconveniences for patients undergoing chemotherapy. Despite standard preventive treatment, chemotherapy-induced nausea and vomiting (CINV) still occurs in approximately 50% of these patients. In an attempt to optimize this treatment, we evaluated the possible effects of carbamazepine for prevention of CINV. DESIGN AND LOCATION: Prospective nonrandomized open-label phase II study carried out at a Brazilian public oncology service. METHODS: Patients allocated for their first cycle of highly emetogenic chemotherapy were continuously recruited. In addition to standard antiemetic protocol that was made available, they received carbamazepine orally, with staggered doses, from the third day before until the fifth day after chemotherapy. Considering the sparseness of evidence about the efficacy of anticonvulsants for CINV prevention, we used Simon’s two-stage design, in which 43 patients should be included unless overall complete prevention was not achieved in 9 out of the first 15 entries. The Functional Living Index-Emesis questionnaire was used to measure the impact on quality of life. RESULTS: None of the ten patients (0%) presented overall complete prevention. In three cases, carbamazepine therapy was withdrawn because of somnolence and vomiting before chemotherapy. Seven were able to take the medication for the entire period and none were responsive, so the study was closed. There was no impact on the patients’ quality of life. CONCLUSION: Carbamazepine was not effective for prevention of CINV and also had a deleterious sideeffect profile in this population. CLINICAL TRIAL REGISTRATION: NCT01581918
Downloads
References
Warr DG. Chemotherapy-and cancer-related nausea and vomiting. Curr Oncol. 2008;15(Suppl 1):S4-9.
Herrstedt J, Dombernowsky P. Anti-emetic therapy in cancer chemotherapy: current status. Basic Clin Pharmacol Toxicol. 2007;101(3):143-50.
Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 2006;24(27):4472-8.
Wickham R. Best practice management of CINV in oncology patients:
II. Antiemetic guidelines and rationale for use. J Support Oncol. 2010;8(2 Suppl 1):10-5.
Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23):2482-94.
Frame DG. Best practice management of CINV in oncology patients:
I. Physiology and treatment of CINV. Multiple neurotransmitters and receptors and the need for combination therapeutic approaches. J Support Oncol. 2010;8(2 Suppl 1):5-9.
Roila F, Donati D, Tamberi S, Margutti G. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer. 2002;10(2):88-95.
Kris MG, Roila F, De Mulder PH, Marty M. Delayed emesis following anticancer chemotherapy. Support Care Cancer. 1998;6(3):228-32.
Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189-98.
Jordan K, Hinke A, Grothey A, et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy- induced emesis. Support Care Cancer. 2007;15(9):1023-33.
Bonneterre J, Chevallier B, Metz R, et al. A randomized double- blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J Clin Oncol. 1990;8(6):1063-9.
Fujii M, Kanke M, Arai Y, et al. [A randomized crossover comparison of azasetron alone and azasetron plus dexamethasone for the prevention of nausea and vomiting by chemotherapy including cisplatin]. Gan To Kagaku Ryoho. 2000;27(10):1557-63.
Ioannidis JP, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta- analysis of randomized evidence. J Clin Oncol. 2000;18(19):3409-22.
Navari RM, Reinhardt RR, Gralla RJ, et al. Reduction of cisplatin- induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med. 1999;340(3):190-5.
Warr DG, Hesketh PJ, Gralla RJ, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23(12):2822-30.
Cruz FM, de Iracema Gomes Cubero D, Taranto P, et al. Gabapentin for the prevention of chemotherapy- induced nausea and vomiting: a pilot study. Support Care Cancer. 2012;20(3):601-6.
Strohscheer I, Borasio GD. Carbamazepine-responsive paroxysmal nausea and vomiting in a patient with meningeal carcinomatosis. Palliat Med. 2006;20(5):549-50.
Decker GM, DeMeyer ES, Kisko DL. Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. J Support Oncol. 2006;4(1):35-41, 52.
Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1-10.
Hahn NM, Zon RT, Yu M, et al. A phase II study of pemetrexed as second-line chemotherapy for the treatment of metastatic castrate- resistant prostate cancer (CRPC); Hoosier Oncology Group GU03-67. Ann Oncol. 2009;20(12):1971-6.
Lasoń W, Dudra-Jastrzębska M, Rejdak K, Czuczwar SJ. Basic mechanisms of antiepileptic drugs and their pharmacokinetic/ pharmacodynamic interactions: an update. Pharmacol Rep. 2011;63(2):271-92.
Tan L, Liu J, Liu X, et al. Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res. 2009;28:131.
Harousseau JL, Zittoun R, Bonneterre J, Hedouin M, Ouvry J. Amélioation du contrôle des nausées et vomissements lors d’une chimithérapie modérément émétisnate, par l’association ondansétron méthylprednisolone et lorazépam, antiémétique antérieure [Improvement in the control of chemotherapy induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic treatment and uncontrolled by a previous antiemetic combination]. Bull Cancer. 2000;87(6):491-7.
Meden H, Meissner O, Conrad A, Kuhn W. Improved control of nausea and emesis with a new bromazepam-containing ondansetron regimen in ovarian cancer patients receiving chemotherapy with carboplatin and cyclophosphamide. Eur J Gynaecol Oncol. 1996;17(2):114-22.
Mander AP, Thompson SG. Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials. Contemp Clin Trials. 2010;31(6):572-8.
